Company profile for PharmaTher

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals such as ketamine and psilocybin, for FDA approval to treat mental health, neurological and pain disorders.Our team includes world-class strategic partners, advisors and a strong leadership team with a proven track recor...
PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals such as ketamine and psilocybin, for FDA approval to treat mental health, neurological and pain disorders.Our team includes world-class strategic partners, advisors and a strong leadership team with a proven track record of success in drug development, business development and capital markets. Our goal is to advance the development of panaceAI™, our drug repurposing artificial intelligence platform, and advance our clinical product.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Canada
Address
Address
82 Richmond Street East Toronto, Ontario
Telephone
Telephone
1-888-846-3171
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/10/02/3160310/0/en/PharmaTher-Provides-Corporate-Update-on-Ketamine-Development-and-Commercial-Strategy.html

GLOBENEWSWIRE
02 Oct 2025

https://www.globenewswire.com/news-release/2025/10/01/3159435/0/en/PharmaTher-Announces-Sale-of-Ketamine-ANDA-with-Potential-to-Generate-Over-US-25-Million-in-Milestone-and-Profit-Sharing-Payments.html

GLOBENEWSWIRE
01 Oct 2025

https://www.globenewswire.com/news-release/2025/08/26/3139203/0/en/PharmaTher-Provides-Corporate-Update-Following-FDA-Approval-of-Ketamine-KETARx.html

GLOBENEWSWIRE
26 Aug 2025

https://www.globenewswire.com/news-release/2025/08/14/3133406/0/en/PharmaTher-Founder-and-CEO-Issues-Letter-to-Shareholders-following-the-FDA-Approval-of-Ketamine-KETARx.html

GLOBENEWSWIRE
14 Aug 2025

https://www.globenewswire.com/news-release/2025/08/11/3130994/0/en/PharmaTher-Announces-FDA-Approval-of-Ketamine-KETARx.html

GLOBENEWSWIRE
11 Aug 2025

https://www.globenewswire.com/news-release/2025/07/02/3109115/0/en/PharmaTher-Announces-Path-to-Ketamine-Commercialization-with-No-Planned-Financing-Confirms-FDA-Approval-Goal-Date-of-August-9th-2025-for-Ketamine.html

GLOBENEWSWIRE
02 Jul 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty